Cimetidine-induced augmentation of human lymphocyte blastogenesis by mitogen, bacterial antigen, and alloantigen.
Cimetidine-induced augmentation of human lymphocyte blastogenesis by mitogen, bacterial antigen, and alloantigen.
复制标题
西咪替丁通过有丝分裂原、细菌抗原和同种异体抗原诱导人淋巴细胞胚细胞发生增强。
DOI：
10.1097/00007890-198002000-00011
复制
发表时间：
1980
期刊：
影响因子：
6.2
通讯作者：
J. Schmidtke
中科院分区：
文献类型：
--
作者：
R. Gifford;S. Hatfield;J. Schmidtke
评估了组胺 2 型受体拮抗剂西咪替丁对正常人外周血淋巴细胞 (PBL) 体外增殖反应的影响。与未药物处理的对照值相比，西咪替丁 (10(-3) 至 10(-8) M) 使有丝分裂原诱导的胚芽发生增加了 22%（植物血凝素 (PHA) 和商陆）（PHA 和商陆的 P 小于 005）。将 PBL 与西咪替丁预孵育可进一步将胚芽发生增强 2 至 3 倍（P 小于0.005（两种有丝分裂原）。当使用细菌抗原（链激酶-链球菌酶）或同种异体抗原诱导胚细胞发生时，对同一正常受试者进行的多次测试表明，西咪替丁的增殖反应具有统计学上的显着放大作用，西咪替丁的最佳有效浓度范围为 10(-5) 至 10(-7) M，这与预期的临床血清水平相对应。这些观察结果表明，在没有外源添加组胺的情况下，组胺 2 型受体拮抗剂能够调节 PBL 的增殖反应。我们讨论了这种西咪替丁诱导的增殖增强的免疫调节意义与临床移植和癌症免疫治疗的关系。
The effect of Cimetidine, a histamine-type 2 receptor antagonist, was evaluated on the in vitro proliferative response of normal human peripheral blood lymphocytes (PBLs). Cimetidine (10(-3) to 10(-8) M) increased mitogen-induced blastogenesis by 22% (phytohemagglutinin (PHA) and by 27% (pokeweed) over nondrug-treated control values (P less than 005 for PHA and pokeweed). Preincubation of PBLs with Cimetidine further augmented blastogenesis as much as 2- to 3-fold (P less than 0.005 for both mitogens). Multiple testing of the same normal subject demonstrated consistent reproducibility of increased proliferation by Cimetidine. Similar statistically significant amplifications of the proliferative res-ponse were observed when bacterial antigen (streptokinase-streptodornase) or alloantigen was used to induce blastogenesis. Optimally effective concentrations of Cimetidine ranged from 10(-5) to 10(-7) M, which corresponds to expected clinical serum levels. These observations suggest that a histamine-type 2 receptor antagonist is capable of modulating the proliferative response of PBLs in the absence of exogenously added histamine. The immunoregulatory implication of this Cimetidine-induced proliferative augmentation is discussed in relation to clinical transplantation and cancer immunotherapy.